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Abstract
Background: The mechanisms of benefit of mineralocorticoid receptors antagonists in congestive heart failure
(CHF) are still debated. We hypothesized that aldosterone contributes to pulmonary remodelling and right
ventricular (RV) dysfunction associated with CHF by stimulation of lung myofibroblasts (MYFs) proliferation.
Methods: Rats with moderate to large myocardial infarcts (MI) and CHF were studied. Two weeks after MI,
spironolactone 100 mg/kg/day (n = 21) or no treatment (n = 24) were given for 3 weeks and compared to sham
(n = 8).
Results: Infarct size was similar by ultrasound and pathologic measures in both MI groups.
The MI-untreated group developed important lung remodelling with nearly doubling of dry lung weight (p < 0.01),
reduced left ventricular (LV) fractional shortening (16 ± 2% vs. 53 ± 1%; mean ± SEM, p < 0.0001), pulmonary
hypertension (RV systolic pressure: 40 ± 3 mmHg vs. 27 ± 1 mmHg, p < 0.01) and RV hypertrophy (RV/(LV +
septum): 38 ± 3% vs. 24 ± 1%, p < 0.05). Spironolactone had no effect on these parameters and did not improve
LV or RV performance (tricuspid annular plane systolic excursion and RV myocardial performance index) measured
by echocardiography. CHF induced a restrictive respiratory syndrome with histological lung fibrosis: this was also
unaffected by spironolactone. Finally, isolated lung MYFs did not proliferate after exposure to aldosterone.
Conclusion: Aldosterone does not significantly contribute to pulmonary remodelling and RV dysfunction
associated with CHF. Other mechanisms are responsible for the beneficial effects of spironolactone in CHF.
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Background
Pulmonary hypertension (PH) is a frequent complication
of congestive heart failure (CHF). Conversely, left heart
disease represents the single most prevalent causative fac-
tor for PH. PH, especially when associated with right ven-
tricular (RV) dysfunction, reduces exercise capacity and
represents an important independent prognostic factor in
CHF [1]. At the core of pulmonary adaptations to CHF
lies pulmonary structural remodelling with abundant pro-
liferation of alveolar wall myofibroblasts (MYFs) [2-5].
MYFs are star-shaped cells that have a physiological role
in growth, development and repair of tissue, and express
morphological characteristics of both fibroblasts and
smooth muscle cells [3]. The proliferation of MYFs is also
associated with collagen and reticulin deposition in the
alveolar septa, leading to thickening of capillary endothe-
lial and alveolar epithelial cell basement membranes,
which results in reduced lung compliance [3-7]. Although
these adaptive mechanisms provide protection against
alveolar oedema formation, they induce a maladaptive
restrictive lung syndrome, affecting lung mechanics and
gas exchange and contributing to the loss of functional
capacity of CHF subjects [5,6]. The reduction of total lung
capacity is proportional to the severity of heart disease as
measured from cardiopulmonary exercise testing [8].
Unfortunately, the biologic determinants of lung structural
remodelling associated with CHF are currently unknown.
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The aldosterone antagonists eplerenone and spironolac-
tone are currently approved for the therapy of CHF [9-11]
and constitute a class I recommendation (useful and
recommended) according to the guidelines of the Ameri-
can College of Cardiology/American Heart Association
(ACC/AHA) [12]. Despite proven benefits on reducing
morbidity and mortality, the exact mechanisms of action of
aldosterone inhibition remains debated and several investi-
gators have reported on the underuse of these agents [13].
One of the potential beneficial extra-renal effects of aldos-
terone inhibition is the reduction of cardiac remodelling
[14,15]. Furthermore, the use of spironolactone in CHF has
shown positive effects on lung tissues by improving gas dif-
fusion and exercise capacity [16], suggesting that spirono-
lactone could also have some beneficial effect on lung
remodelling associated with CHF. Pre-clinical studies have
also revealed that aldosterone could play a role in the
development of lung fibrosis [17].
Against this background, we hypothesized that aldoster-
one contributes to lung structural remodelling and the
ensuing pulmonary hypertension and RV dysfunction
associated with CHF by promoting lung MYFs prolifera-
tion and fibrosis. As a corollary, a mechanism of benefit of
spironolactone therapy would be to improve lung remo-
delling, secondary PH and RV dysfunction.
Methods
The animal ethics committee of the Montreal Heart
Institute approved the study protocol. It was implemen-
ted following the guidelines of the Canadian Council on
Animal research in accordance with the Guide for the
Care and Use of Laboratory Animals [18].
Experimental protocol
Myocardial infarction (MI) or sham surgery was per-
formed on male Wistar rats as previously described
[2-4,7,19-21]. Briefly, rats were anaesthetized, intubated
and put on a rodent ventilator (Harvard Apparatus). Then,
a left-sided thoracotomy was realized in order to expose
the heart and a ligation of the proximal left anterior des-
cending coronary artery was performed. The sham group
underwent the same procedure with the exception of the
ligation of the artery.
This study was designed to evaluate animals with CHF
and lung remodelling using a previously validated approach
based on troponin T measurement 24 hours after coronary
ligation [7,19]. Plasma troponin-T ≥ 5.1 μg/L predicts
moderate to large infarct size (≥ 30% left ventricular (LV)
wall motion abnormality) with a sensitivity of 91% and a
specificity of 84% [7,19]. Using this approach we previously
demonstrated that these animals develop lung remodelling,
PH and RV dysfunction. Blood samples were collected via
the subclavian vein, centrifuged and then analyzed by stan-
dard electrochemiluminescence immunoassay using the
Cobas e 601 (Roche). Two weeks after surgery, the selected
rats were randomly divided into 2 groups: MI+spironolac-
tone (Novopharm, 100 mg/kg/day in food; n = 21) and
MI-untreated (n = 24). The sham group (n = 8) did not
receive treatment. These therapies lasted for 3 weeks and
the animals were studies 5 weeks after MI.
Transthoracic echocardiographic study
Each rat was anaesthetized with 2% of isoflurane to
determine LV wall motion score abnormality and LV
and RV functions and geometries using a phased-array
probe 10S (4.5-11.5 Megahertz) linked to a Vivid 7 sys-
tem (GE Healthcare Ultrasound) [2].
In vivo respiratory function tests and hemodynamic
measurements
Ketamine (50 mg/kg) and xylazine (10 mg/kg) were
administered and the trachea was isolated. A tracheot-
omy was performed and an endotracheal tube was
installed. To determine lung compliance, lung elastance
and measure respiratory function, rats were connected
to a computer-controlled small-animal ventilator (Flexi-
Vent, Scireq) as previously described [2]. Respiratory
pressure-volume (P-V) loops were produced for each
animal and analyzed using the Salazar-Knowles equa-
tion: V = A - B·e-KP. Where, A is the estimate of the
inspiratory capacity, B is the estimate of total lung capa-
city (P = 0), K is the curvature parameter of P V loop,
P is the pressure and V is the volume.
Using a Powerlab polygraph system (AD Instruments),
LV and RV hemodynamic parameters were measured by
the isolation and incision of the right jugular vein and
carotid artery followed by the insertion of high fidelity
pressure catheters (Millar Instruments) in the RV and
LV.
Lung and heart morphometric and histological
measurements
Morphometric measurements were performed as pre-
viously described [2]. First, the right middle lung was
isolated and weighed (wet weight). The lobe was dried
for two weeks before measuring dry weight. Pulmonary
oedema was determined by the ratio of dry/wet lung
weights. The left lung was perfused and fixed with opti-
mal cutting temperature compound (OCT, Sakura), then
snap-frozen in liquid nitrogen to finally be frozen in 2-
methylbutane for later study.
The hearts were isolated and dissected to separate the
left and right ventricles in order to assess RV hypertro-
phy (RVH) by weight. LV scars were dissected and
weighed and their surface area determined by
planimetry.
Histological slides of lung and LV tissue from sham (n =
8), MI-untreated (n = 10) and MI+spironolactone (n = 10)
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were stained with Masson’s trichrome. For each slide, 10
random visual fields (10X) were analyzed with the Image-
pro Plus 6.2 software (Media Cybernetics) to determine the
collagen-staining ratio.
RT-PCR for osteopontin (OPN) gene expression
Lung samples form sham (n = 8), MI-untreated (n = 10)
and MI+spironolactone (n = 10) were prepared and stu-
dies. Real-time PCR was performed with the Platinum
SYBR Green qPCR Kit SuperMix-UDG (Invitrogen) with
use of the MX3005P device (Stratagene). To evaluate the
expression of OPN gene in the lungs, the oligos of rat
OPN forward [TCAGATGCTGTAGCCACTTG]; rat
OPN reverse [TTCACAGAATCCTCGCTCTC]; rat cyclo
A housekeeping gene forward [CTGATGGCGAGCCCT
TGG] and rat cyclo A reverse [GCCACCAGTGCCAT-
TATG] were used.
Lung MYFs isolation and proliferation
Lung MYFs of male Wistar rats (175-200 g) were isolated
as previously described [2,4]. Briefly, rats were anaesthe-
tized with intramuscular injection of a ketamine/xylazine
solution (1 ml/kg). After thoracotomy, the peripheral
regions of each lung lobe were dissected and cut into
pieces of about 3-5 mm and washed twice in a Hank’s
Balanced Salt Solution (HBSS) containing 0.5% Ciprofloxa-
cin. Subsequently, tissues were placed in a 0.1% trypsin
solution overnight at 4°C with stirring to be digested. The
next day, lung tissues were digested some more by up and
down pipetting motion in a 0.1% collagenase II solution
until solution appeared cloudy, then it was centrifuged at
3000 RPM for 3 minutes at 4°C. The pellets were re-sus-
pended in HBSS and re-centrifuged twice. The final pellet
was dissolved in 50 ml of Dulbecco’s modified Eagle’s
medium (DMEM) containing 6.7% Fetal Bovine Serum
(FBS), 1.8% Penicillin-Streptomycin, 0.9% Amphotericin B
and 0.5% Ciprofloxacin. Lung cells were then plated in
T-75 flasks in an incubator (Sanyo Scientific) maintained
at 37°C and 5% CO2. These are ideal conditions to stimu-
late cell proliferation. The culture medium (FBS) was
changed every 2 days until confluence. MYFs were pas-
saged with Trypsin-EDTA 1X at 37°C and plated in
96-wells plates (1500 cells/200 ul) for CyQUANT cell pro-
liferation assay.
CyQUANT cell proliferation assay
After reaching confluence again (around 24 hours), the
first-pass lung MYFs in 96-wells plate were starved for
24 hours with a serum-free media made of DMEM con-
taining 0.2% ITS (Insulin, Transferrine and Selenium)
and 2% Penicillin-Streptomycin. Thereafter, the cells
were treated for 48 hours with one of the following
three solutions: FBS positive control, ITS negative con-
trol and aldosterone (Sigma) 10-7M (n = 26) or 10-6M
(n = 23). After treatment, the culture medium was
removed and the 96-wells plates were frozen for at least
72 hours. Cellular proliferation was then determined
using the CyQUANT Cell proliferation Assay Kit (Invi-
trogen) following the manufacturer’s instructions.
Statistical analysis
Parameters from the 3 experimental groups were evalu-
ated by a one-way analysis of variance (ANOVA) fol-
lowed, when a significant interaction was found (p <
0.05), by the Fisher’s post hoc test for multiple groups
comparisons. All values were expressed as mean±SEM
and values of p < 0.05 were considered to be statistically
significant.
Results
From the moment of randomization to treatment (2
weeks post MI) until the end of study (5 weeks), there
was no mortality in any group. Plasma troponin-T
concentrations measured 24 h after infarct was similar
in the MI-untreated (8.5 ± 0.4 μg/l) and the MI+spiro-
nolactone (9.1 ± 0.3 μg/l) groups indicating compar-
able myocardial injury prior to treatment allocation
(Table 1). Five weeks after MI, this translated into
moderate to severe CHF as evaluated from hemody-
namics and echocardiography.
Table 1 LV and RV echocardiographic parameters
Sham MI-untreated MI+spironolactone
LV wall motion abnormality (%) 0 50 ± 5* 50 ± 4*
LV wall motion score index 1 ± 0 1.95 ± 0.06* 1.79 ± 0.07*
LV end-diastolic dimension (mm) 8.2 ± 0.1 11.2 ± 0.2* 10.8 ± 0.2*
LV end-systolic dimension (mm) 3.9 ± 0.1 9.5 ± 0.3* 9.0 ± 0.3*
LV end-diastolic area (mm2) 49 ± 1 92 ± 3* 85 ± 3*
LV end-systolic area (mm2) 11 ± 1 64 ± 4* 58 ± 4*
TVc-o (msec) 103 ± 10 119 ± 6 121 ± 6
RV end-diastolic dimension (mm) 3.2 ± 0.1 3.4 ± 0.1 3.3 ± 0.2
LV, left ventricular; RV, right ventricular; TVc-o, tricuspid valve closing to opening.
*p < 0.0001 vs. Sham.
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Effects of spironolactone on LV function and LV
remodelling
Echocardiographic LV wall motion abnormality (50 ± 4%
vs. 50 ± 5%) and wall motion score index (WMSI) were
similar in the MI-untreated and MI+spironolactone
groups (table 1). The LV was dilated with increases in LV
end-diastolic and end-systolic dimensions and LV end-
diastolic and end-systolic areas (p < 0.0001) with no
effect of spironolactone treatment (table 1). Compared to
sham, LV fractional shortening (FS, 16 ± 2% vs. 53 ± 1%;
p < 0.0001, Figure 1A) and fractional area change (FAC,
32 ± 2% vs. 77 ± 2%; p < 0.0001, Figure 1B) were
decreased, also without significant effect of spironolac-
tone therapy.
Hemodynamic parameters are presented in table 2. LV
end-diastolic pressure (LVEDP) similarly increased in
both MI groups but did not reach statistical significance.
Indices of LV contractility (LV(+) dP/dt) and relaxation
(LV(-) dP/dt) were importantly reduced after MI (p <
0.0001) with no beneficial effect of MR antagonism.
Pathologic LV scar evaluations were performed. Scar
weight, scar weight/BW ratio, scar surface and scar
weight/scar surface ratio were similar in the MI-
untreated and MI-spironolactone groups (table 3).
Finally, LV histological study revealed that LV collagen
fractional area was highly and similarly increased in MI-
untreated and MI+spironolactone groups (17 ± 2%, 19 ±
2%; p < 0.0001) compared to the sham group (2.9 ± 0.3%,
Figure 2).
Effects of spironolactone on PH and the development of
RV dysfunction and hypertrophy
MI-untreated rats developed moderate PH evidenced by a
significant increase in RV systolic pressure (40 ± 3 mmHg)
compared to sham (27 ± 1 mmHg, p < 0.01). Spironolac-
tone therapy did not modify this increase in RV systolic
Figure 1 Effect of spironolactone on echocardiographic left ventricular function in sham, myocardial infarct (MI) and MI
+spironolactone rats. (A) left ventricular fractional shorting (LV FS), (B) LV fractional area change (LV FAC), (C) Right ventricular myocardial
performance index (RV MPI) and (D) Right ventricular tricuspid annulus plane systolic excursion (RV TAPSE). Results are expressed as mean±SEM.
*p < 0.0001 vs. Sham; †p < 0.05 vs. Sham.
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pressure that remained similarly elevated at 38 ± 3 mmHg
(Figure 3A). This elevation of pulmonary pressure in CHF
animals was associated with RV hypertrophy revealed by a
significant rise of RV/(LV+Septum) weights ratio from
23 ± 1% in sham rats to 38 ± 3% (p < 0.05) in the MI-
untreated group. Spironolactone also did not reduce RV
hypertrophy (39 ± 3%; p < 0.01, Figure 3B).
Parameters from the echocardiographic examinations
of the RV are presented in table 1. There was a non-
significant increase of tricuspid valve closing to opening
time (TVc-o) in the CHF groups compared to the con-
trol group. Similar findings were found for RV myocar-
dial performance index (MPI, Figure 1C). The tricuspid
annulus plane systolic excursion (TAPSE), estimating
RV systolic function, was significantly and similarly
diminished in the CHF groups (Figure 1D).
As previously demonstrated in this model, RV hemo-
dynamic measurements revealed an increase of indices
of RV contractility (RV(+) dP/dt, p = ns) and relaxation
(RV(-) dP/dt, p < 0.05) in the MI-untreated group, with
no effect of spironolactone (table 2).
Effects of spironolactone on lung structural remodelling
and respiratory function
CHF almost doubled the ratio of the wet lung weight/
BW from 0.08 ± 0.01% in sham rats to 0.17 ± 0.02% in
the MI-untreated group (Figure 4A). This increase was
the result of important lung structural remodelling since
the ratio of the dry lung weight/BW also doubled from
0.018 ± 0.002% in sham rats to 0.037 ± 0.003% in MI-
untreated group (Figure 4B). Consequently, there was
no significant change in dry/wet lung weight ratio (around
22% for the 3 groups) confirming that no pulmonary
oedema was present at this stage of CHF (Figure 4C).
Once again, spironolactone therapy did not modify lung
structural remodelling. Further evidence of lung remodel-
ling was found at histological studies (Figure 5). Collagen
fractional area doubled in the MI-untreated and MI+spiro-
nolactone animals (23 ± 3% and 21 ± 3%, respectively)
compared to sham (11 ± 1%, p < 0.05).
Respiratory function studies revealed that CHF caused a
restrictive lung syndrome (Figure 6). There was a decrease
(p < 0.01) in respiratory compliance, from 1.30 ± 0.05 ml/
cmH20 in sham to 0.98 ± 0.06 ml/cmH20 in the MI group
(Figure 6A). However, MR antagonism could not restore
lung compliance (0.94 ± 0.06 ml/cmH20). Unsurprisingly,
CHF significantly increased respiratory elastance (the
inverse of compliance, p < 0.05 vs. sham), which was
not reversed by spironolactone (table 3). The respiratory
pressure-volume loop depicts this restrictive syndrome
with a downward and rightward shift of the curve in CHF
(Figure 6B), indicative of lower respiratory volumes at
higher inflation pressures. The fitted Salazar-Knowles para-
meters (A, B and K) were consequently reduced compared
Table 3 Effect of spironolactone on BW, heart morphometric and respiratory function parameters
Sham MI MI+spironolactone
Body Weight (g) 431 ± 9 417 ± 8 392 ± 6**‡
Scar Weight (g) N/A 0.14 ± 0.02* 0.12 ± 0.02**
Scar Weight/Body Weight (%) N/A 0.033 ± 0.005† 0.04 ± 0.01†
Scar Surface (mm2) N/A 115 ± 9* 111 ± 8*
Scar Weight/Scar Surface (g/mm2) N/A 0.111 ± 0.008* 0.097 ± 0.008*
Respiratory elastance (cmH2O/ml) 0.78 ± 0.03 1.2 ± 0.1† 1.2 ± 0.1†
A Parameter, Salazar-Knowles 11.0 ± 0.2 9.6 ± 0.3† 9.3 ± 0.4**
B Parameter, Salazar-Knowles 17.9 ± 0.7 13.8 ± 0.8** 13.5 ± 0.8**
K Parameter, Salazar-Knowles 0.173 ± 0.005 0.148 ± 0.006† 0.145 ± 0.006†
A, estimate of the inspiratory capacity; B, estimate of total lung capacity (p = 0); K, curvature parameter of P-V loop.
*p < 0.0001 vs. Sham; **p < 0.01 vs. Sham; †p < 0.05 vs. Sham; ‡p < 0.05 vs. MI.
Table 2 Hemodynamic parameters
Sham MI-untreated MI+spironolactone
Heart Rate (bpm) 280 ± 12 244 ± 8** 238 ± 6**
MAP (mmHg) 97 ± 7 89 ± 4 84 ± 2†
LVEDP (mmHg) 10 ± 1 16 ± 2 16 ± 2
LV (+) dP/dt (mmHg/s) 7843 ± 491 5121 ± 317* 5156 ± 152*
LV (-) dP/dt (mmHg/s) -6214 ± 357 -3205 ± 238* -3164 ± 187*
RV (+) dP/dt (mmHg/s) 1387 ± 92 1688 ± 99 1538 ± 124
RV (-) dP/dt (mmHg/s) -928 ± 67 -1248 ± 72† -1133 ± 92
MAP, mean arterial pressure; LV, left ventricular; LVEDP, LV end diastolic pressure; RV, right ventricular.
*p < 0.0001 vs. Sham; **p < 0.01 vs. Sham; †p < 0.05 vs. Sham.
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to the sham group (table 3). Spironolactone therapy did not
reverse the adverse effects of CHF on respiratory function.
Finally, RT-PCR analysis revealed that CHF induced a 5-
fold augmentation of OPN gene expression in the lung
(1.5 ± 0.1 relative units, Figure 7) compared to control
group (0.3 ± 0.1 relative units, p < 0.0001). MR antagon-
ism succeeded to significantly reduce OPN gene expres-
sion in the lung (1.1 ± 0.1 relative units; p < 0.05 vs. MI).
Isolated lung MYFs in cell culture revealed that aldoster-
one treatments for 48 h did not increase lung MYFs prolif-
eration rate (Figure 8).
Discussion
We evaluated the effects of MR antagonism on pulmonary
hypertension, lung structural remodelling and RV function
in CHF. After moderate to large MI, rats developed CHF
with PH, RV dysfunction, RV hypertrophy and important
lung structural remodelling characterized by alveolar wall
collagen deposition causing a restrictive respiratory syn-
drome. Contrary to our hypothesis however, spironolac-
tone therapy had no significant impact on these pathologic
modifications. Mechanistically, lung tissue gene expression
of the pro-fibrotic mediator OPN was increased in CHF,
and reduced in spironolactone-treated animals, but isolated
lung MYFs failed to proliferate after aldosterone stimula-
tion. Taken together, these data indicate that aldosterone
does not play a central role in promoting lung MYFs prolif-
eration and in contributing to lung structural remodelling
and RV dysfunction associated to CHF.
Major clinical trials (RALES, EPHESUS and EMPHA-
SIS-HF) have convincingly demonstrated that the aldos-
terone antagonists eplerenone and spironolactone
reduce mortality and morbidity when added to optimal
medical therapy [9-11]. Antagonism of MR is useful,
effective and recommended in moderate to severe CHF
according to the ACC and AHA guidelines [12,13].
Figure 2 Effect of spironolactone of myocardial fibrosis in sham, myocardial infarction (MI) and MI+spironolactone rats. Quantitative
analysis of LV collagen fractional area (A) and histological LV section with Masson’s trichrome staining where blue represent collagen in sham
(B), MI (C) and MI+spironolactone (D) groups. Results are expressed as mean±SEM. *p < 0.0001 vs. Sham.
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With this study, we had the opportunity to find one
possible and as yet unexplored mechanism of the dele-
terious actions of aldosterone in CHF: its potential effect
on lung remodelling and RV function.
Some specific points must be considered when inter-
preting this negative study by comparison to previous
pre-clinical trials evaluating MR antagonism in this CHF
model. We were very careful in the timing of therapy
Figure 3 Pulmonary hypertension and RV hypertrophy in sham, myocardial infarct (MI) and MI+spironolactone. (A) right ventricular
systolic pressure (RVSP) and (B) right ventricular hypertrophy (RVH). Results are expressed as mean±SEM. **p < 0.01 vs. Sham; †p < 0.05 vs. Sham.
Chabot et al. BMC Cardiovascular Disorders 2011, 11:72
http://www.biomedcentral.com/1471-2261/11/72
Page 7 of 13
and the severity of CHF studied. First, we used a treat-
ment strategy rather than a preventive approach since
we started treatment 2 weeks after MI, at a time when
CHF is well established and when PH and lung
remodelling is already present. Second, we prospectively
selected medium to large MIs based on 24 h troponin T
measurements. Using this previously validated approach,
we randomized rats with established CHF and already
Figure 4 Lung remodelling in sham, myocardial infarct (MI) and MI+spironolactone rats. (A) wet lung weight/body weight (BW), (B) dry
lung weight/body weight (BW) and (C) dry/wet lung weights. Results are expressed as mean±SEM. **p < 0.01 vs. Sham.
Chabot et al. BMC Cardiovascular Disorders 2011, 11:72
http://www.biomedcentral.com/1471-2261/11/72
Page 8 of 13
evident lung remodelling. Third, we specifically evalu-
ated lung and RV pathology and functions as end-
points.
Other investigators previously evaluated MR antago-
nists after MI in rats. Two important distinguishing
points should be noted: first, none of these studies
selected animals with more severe CHF, PH and lung
remodelling and; second, none specifically studied lung
pathology and function. Lal et al. administered spirono-
lactone (80 mg/kg/day) starting 1 to 3 days only after
MI for 6 weeks [22]. This “prevention” study found that
early administration could restore heart function by
improving LV hemodynamics and preventing LV and
RV dilatation. In another prevention study, Takeda et al.
used 100 mg/kg/day of spironolactone started immedi-
ately after MI for 2 weeks and also found that treatment
significantly improved LV function and reduced intersti-
tial myocardial fibrosis [23]. Another study using a
lower dose of spironolactone (20 mg/kg/day) started
immediately after MI for 1 month demonstrated no sig-
nificant impact on LV function and infarct size [24].
These previous prevention studies therefore suggest that
early therapy after MI is beneficial, at least in part, by
preventing LV remodelling and improving LV function
but that the lower dosage of 20 mg/kg/day is ineffective
in rats.
There was only one previous “treatment” study in the
rat MI model: Mulder et al. used 80 mg/kg/day of spiro-
nolactone started 8 days after MI for a duration 90 days
[25]. This is the only study, aside from ours, which left
some time for CHF to develop and their results were in
agreement with some of our findings. The authors
found no effect of therapy on LV hemodynamics and
function, although there was a significant effect on LV
collagen density measured by Sirius Red staining. A
potential explanation for the difference with our study
Figure 5 Lung fibrosis in sham, myocardial infarction (MI) and MI+spironolactone rats. quantitative analysis of lung collagen fractional
area (A) and histological lung section with Masson’s trichrome staining where blue represent collagen in sham (B), MI (C) and MI
+spironolactone (D) groups. Results are expressed as mean±SEM. †p < 0.05 vs. Sham.
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on this aspect might be that the LV collagen deposition
can be reduced after 8 days, but not after 14 days and
that infarct size may play an important role as large
infarct may be less influenced by MR blockade due to a
more important activation of other pro-fibrotic media-
tors. In conclusion, our results do not contradict the
pre-clinical evidence suggesting the importance of early
MR antagonism in ischemic CHF to prevent LV remo-
delling and dysfunction. Our results confirm little if any
benefit of administration on LV remodelling and func-
tion when administered later in the disease process and
establish for the first time the lack of effect on estab-
lished lung remodelling and function and on RV
dysfunction.
A negative study always raises the possibility of meth-
odological difficulties that would render the study
inconclusive. The dosing of spironolactone was chosen
based of previously demonstrated effective dosing
Figure 6 Respiratory function testing in sham, myocardial infarct (MI) and MI+spironolactone rats. (A) lung compliance and (B)
respiratory pressure-volume loops. Results are expressed as mean±SEM. **p < 0.01 vs. Sham.
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regimens. We in fact did find a significant biological
effect of spironolactone since lung OPN gene expression
was reduced by therapy. OPN is a glycosylated phospho-
protein playing a role in tissue repair and remodelling.
OPN is expressed constitutively in healthy lungs and
there is prominent OPN expression in lung fibrosis [26].
The expression of OPN has been shown essential for
MYFs differentiation [27]. The reduction of OPN
Figure 7 Effect of spironolactone on lung tissue Osteopontine (OPN) expression in sham, myocardial infarction (MI) and MI
+spironolactone rats assessed by T-qPCR. Results are expressed as mean±SEM. *p < 0.0001 vs. Sham and ‡p < 0.05 vs. MI.
Figure 8 Lung myofibroblasts (MYFs) proliferation with insulin transferrine selenium (ITS) negative control, aldosterone 10-7 M (A),
aldosterone 10-6 M (B) and fetal bovine serum (FBS) positive control. Results are expressed as mean±SEM. §p < 0.0001 vs. aldosterone and
#p < 0.0001 vs. ITS.
Chabot et al. BMC Cardiovascular Disorders 2011, 11:72
http://www.biomedcentral.com/1471-2261/11/72
Page 11 of 13
expression by spironolactone in our model was evidently
insufficient to reverse remodelling suggesting that other
pathways would be predominant. Furthermore, we pre-
viously demonstrated, using the same model and tem-
poral strategy, that the HMG-CoA reductase inhibitor
Atorvastatin could importantly reduce lung remodelling
and fibrosis in this model while reducing isolated lung
MYF proliferation. Atorvastatin also increased total lung
eNOS protein expression compared to CHF suggesting
that structural remodelling could be modulated through
Rho-kinase and eNOS pathways. On the other hand, the
endothelin receptor antagonist Bosentan, used at a
dosage effective in models of pulmonary arterial hyper-
tension, also failed to improve lung structural remodel-
ling and PH in our CHF model. Taken together, these
results suggest that in advanced stages of CHF with
established lung remodelling and fibrosis, blockade of
MR receptors provides no significant benefit on respira-
tory function and PH. Therefore, other pro-fibrotic and
proliferation pathways are more important than aldos-
terone in the maintenance of pathological lung remodel-
ling in CHF.
Our results are not generalizable and must be inter-
preted in the particular context of the study design. In
particular, spironolactone was tested alone to isolate the
effect of MR blockade. In human chronic CHF, spirono-
lactone or eplerenone are generally used as add-on ther-
apy on top of angiotensin-converting enzyme inhibitors
or angiotensin receptor antagonists, beta-blockers,
diuretics and sometimes digitalis. Although we deem
this unlikely, MR antagonist as add-on therapy may ben-
efit form synergistic effects and provide some benefit on
lung remodelling if tested in that context. Our results
are evidently not applicable to patients receiving MR
antagonism started early after MI, at a time when myo-
cardial remodelling is occurring and prior to lung remo-
delling. As discussed above, pre-clinical studies would
suggest maximal benefit to these patients. Furthermore,
we previously demonstrated that irbesartan, an angio-
tensin II receptor antagonist, had completely reversed
the PH, RVH and lung remodelling consequent to CHF
when started immediately after MI [3].
Conclusions
Chronic moderate to severe CHF in rats causes lung
structural remodelling with interstitial fibrosis producing
a restrictive respiratory syndrome contributing to RV
dysfunction. MR antagonism with spironolactone does
not reduce these pathologic modifications. Conse-
quently, aldosterone does not significantly contribute to
pulmonary remodelling and RV dysfunction associated
with CHF. Other mechanisms of action must be respon-
sible for the beneficial effects of spironolactone in
chronic CHF.
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